Patents by Inventor Conrad Gentsch

Conrad Gentsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS OF NICOTINIC ACETYLCHOLINE ALPHA 7 RECEPTOR AGONISTS
    Publication number: 20100125063
    Abstract: Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders.
    Type: Application
    Filed: January 20, 2010
    Publication date: May 20, 2010
    Inventors: Hans O. KALKMAN, Joachim NOZULAK, Annick VASSOUT, Konstanze HURTH, Dominik FEUERBACH, Conrad GENTSCH, Graeme BILBE
  • USE OF S-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE FOR THE TREATMENT OF ANXIETY AND BIPOLAR DISORDERS
    Publication number: 20100063029
    Abstract: The present invention relates to the use of a racemate of the compound of formula (I) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said anantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.
    Type: Application
    Filed: November 11, 2009
    Publication date: March 11, 2010
    Inventors: Graeme Bilbe, John F. Cryan, Conrad Gentsch, Kevin Hall Mcallister, Markus Schmutz, Annick Vassout
  • Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
    Patent number: 7638510
    Abstract: The present invention relates to the use of a racemate of the compound of formula (1) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said enantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.
    Type: Grant
    Filed: February 16, 2004
    Date of Patent: December 29, 2009
    Assignee: Novartis AG
    Inventors: Graeme Bilbe, John F. Cryan, Conrad Gentsch, Kevin Hall McAllister, Markus Schmutz, Annick Vassout
  • Combinations of Nicotinic Acetylcholine Alpha 7 Receptor Antagonists
    Publication number: 20080306081
    Abstract: Combinations which comprise at least one nicotinic acetylcholine alpha 7 receptor agonist and at least one compound selected from the group consisting of (a) conventional antipsychotics (b) atypical antipsychotics (c) cognition, attention and/or memory enhancers (d) and to use of these combinations in the treatment of psychiatric disorders.
    Type: Application
    Filed: November 3, 2005
    Publication date: December 11, 2008
    Applicant: NOVARTIS AG
    Inventors: Hans O. Kalkman, Joachim Nozulak, Annick Vassout, Konstanze Hurth, Dominik Feuerbach, Conrad Gentsch, Graeme Bilbe
  • Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders
    Publication number: 20060194791
    Abstract: The present invention relates to the use of a racemate of the compound of formula (1) consisting of at least 85% S-enantiomer and not more than 15% R-enantiomer or of pharmaceutically acceptable salts of said racemate or of the S-enantiomer of formula I or of pharmaceutically acceptable salts of said enantiomer for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or for the treatment of affective and attention disorders; pharmaceutical compositions for that purpose and packages comprising said pharmaceutical compositions together with instructions for the use of said compositions for the treatment of anxiety or other psychiatric disorders with underlying anxiety symptomatologies or of affective and attention disorders.
    Type: Application
    Filed: February 16, 2004
    Publication date: August 31, 2006
    Inventors: Graeme Bilbe, John Cryan, Conrad Gentsch, Kevin McAllister, Markus Schmutz, Annick Vassout
  • MGluR5 antagonists for the treatment of pain and anxiety
    Publication number: 20010056084
    Abstract: The invention provides the use of selective mGluR5 antagonists for the treatment of pain and anxiety, and the use of mGluR antagonists for the treatment of pain, whereby analgesic effect is achieved by interaction of said antagonists primarily or predominantly at peripheral mGluR receptors.
    Type: Application
    Filed: March 29, 2001
    Publication date: December 27, 2001
    Inventors: Hans Allgeier, Nicholas David Cosford, Peter Josef Flor, Fabrizio Gasparini, Conrad Gentsch, Stephen D. Hess, Edwin Carl Johnson, Rainer Kuhn, Mark Tricklebank, Laszlo Urban, Mark Andrew Varney, Gonul Velicelebi, Katharine Walker
  • Use of CRF-antagonists for treating emesis
    Patent number: 6001807
    Abstract: CRF-antagonists are useful in the treatment of emesis.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: December 14, 1999
    Assignee: Novartis AG
    Inventor: Conrad Gentsch